Zhejiang Ausun Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.12%

Zhejiang Ausun Pharmaceutical Co Ltd (603229) has an Asset Resilience Ratio of 0.12% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Zhejiang Ausun Pharmaceutical Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥3.87 Million
≈ $566.99K USD Cash + Short-term Investments

Total Assets

CN¥3.16 Billion
≈ $461.94 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Zhejiang Ausun Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 603229 equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Zhejiang Ausun Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603229 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥3.87 Million 0.12%
Total Liquid Assets CN¥3.87 Million 0.12%

Asset Resilience Insights

  • Limited Liquidity: Zhejiang Ausun Pharmaceutical Co Ltd maintains only 0.12% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Zhejiang Ausun Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Zhejiang Ausun Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
Biotechnology 6.52%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Annual Asset Resilience Ratio for Zhejiang Ausun Pharmaceutical Co Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Zhejiang Ausun Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.13% CN¥3.94 Million
≈ $575.96K
CN¥3.09 Billion
≈ $451.47 Million
+0.05pp
2024-12-31 0.08% CN¥2.24 Million
≈ $328.16K
CN¥2.98 Billion
≈ $436.42 Million
-0.10pp
2022-12-31 0.17% CN¥4.02 Million
≈ $588.13K
CN¥2.32 Billion
≈ $338.81 Million
-5.81pp
2021-12-31 5.98% CN¥110.00 Million
≈ $16.10 Million
CN¥1.84 Billion
≈ $269.17 Million
+5.92pp
2019-12-31 0.06% CN¥542.46K
≈ $79.38K
CN¥886.14 Million
≈ $129.67 Million
-0.05pp
2018-12-31 0.11% CN¥857.79K
≈ $125.52K
CN¥801.98 Million
≈ $117.35 Million
-0.06pp
2016-12-31 0.16% CN¥734.11K
≈ $107.42K
CN¥446.06 Million
≈ $65.27 Million
--
pp = percentage points

About Zhejiang Ausun Pharmaceutical Co Ltd

SHG:603229 China Biotechnology
Market Cap
$986.57 Million
CN¥6.74 Billion CNY
Market Cap Rank
#9117 Global
#2311 in China
Share Price
CN¥8.12
Change (1 day)
-2.17%
52-Week Range
CN¥8.12 - CN¥12.31
All Time High
CN¥1598.02
About

Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, … Read more